📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
48 announcements match the current filters (relevance ≥ 5).
Dr. Reddy's Launches First Generic Semaglutide Injection in Canada (G7 First)
Dr. Reddy's Laboratories has launched its generic Semaglutide injection in Canada, becoming the first company to receive Health Canada approval for this product. Canada represents the first G7 country to grant market authorization for a generic version of this high-demand GLP-1 therapy. The injection is available in 2 mg/pen and 4 mg/pen strengths for the treatment of type 2 diabetes. This move follows the company's recent launch of the same molecule in India under the brand name Obeda, highlighting a strategic global expansion into the lucrative peptide-based diabetes market.
Key Highlights
First company to receive Health Canada approval for generic Semaglutide Injection
Canada is the first G7 country to authorize a generic version of this GLP-1 therapy
Product launched in 2 mg/pen and 4 mg/pen strengths with a concentration of 1.34 mg/ml
Launch follows the receipt of Notice of Compliance (NOC) from Health Canada on April 28, 2026
Strengthens global GLP-1 portfolio following the recent launch of Obeda in India
👀 What to Watch
This launch establishes Dr. Reddy's as a first-mover in the complex generic GLP-1 space within a major regulated market. Investors should monitor the company's ability to capture market share in Canada and potential regulatory filings in other G7 nations.
Dr. Reddy's Q4FY26 Revenue Up 12% to ₹7,516 Cr; Adjusted EBITDA Margin at 19.5%
Dr. Reddy's reported Q4FY26 revenue of ₹7,516 Cr, a 12% YoY increase, though reported PAT fell 86% to ₹220 Cr due to significant one-time charges. These charges included a ₹453 Cr shelf stock adjustment for lenalidomide and ₹228 Cr in R&D impairments. However, the base business remains robust with India growing 20% and Emerging Markets up 29%. The company also achieved a milestone by launching generic semaglutide (Obeda) in India and securing Canadian approval.
Key Highlights
Reported Q4 revenue of ₹7,516 Cr (+12% YoY); FY26 revenue reached ₹33,593 Cr (+3% YoY).
One-time impacts totaling over ₹800 Cr (SSA, Impairment, VAT) dragged down reported Q4 PAT to ₹220 Cr.
India business outperformed market with 20% YoY growth; Emerging Markets grew 29% YoY.
North America revenue declined 51% YoY to ₹1,756 Cr due to lenalidomide price erosion and adjustments.
Maintained a strong balance sheet with a net cash surplus of ₹3,271 Cr as of March 31, 2026.
👀 What to Watch
Investors should look past the one-time impairment and inventory charges to focus on the double-digit growth in the base business and the potential of the Semaglutide launch. The strong cash position and pipeline progress in biosimilars provide a long-term safety net despite US pricing volatility.
Dr. Reddy's Elevates India Head Sandeep Khandelwal to SMP; Appoints AI Expert to Board
Dr. Reddy's has elevated Sandeep Khandelwal, the head of its India business, to the Senior Management Personnel (SMP) group following a period of significant growth where the India topline rose from ₹2,300 crore to ₹7,000 crore. The company also appointed Srikanth Velamakanni, co-founder of AI firm Fractal, as an Independent Director, signaling a strategic push toward digital transformation. Additionally, Deloitte Haskins & Sells has been appointed as the new statutory auditor for a five-year term. These changes reflect a focus on rewarding performance and strengthening governance with technology expertise.
Key Highlights
Sandeep Khandelwal elevated to SMP after growing India business from ₹2,300 Cr to ₹7,000 Cr
India business EBITDA margins expanded from 19% to 24% under Khandelwal's leadership
Company's market rank in India improved from 16th to 9th during his 7-year tenure
Srikanth Velamakanni, Co-founder of Fractal AI, appointed as Independent Director
Deloitte Haskins & Sells, LLP appointed as Statutory Auditors for a 5-year term
👀 What to Watch
Investors should view the elevation of the India head as a positive sign of internal stability and performance-based growth. The addition of an AI-focused board member suggests the company is positioning itself for future-ready digital operations.
Dr. Reddy's Appoints Fractal AI CEO to Board; Elevates India Head After ₹7,000 Cr Revenue Milestone
Dr. Reddy's Laboratories has announced significant leadership updates, including the appointment of Srikanth Velamakanni (Co-founder of Fractal AI) as an Independent Director, signaling a strategic focus on technology. The company also elevated Sandeep Khandelwal to Senior Management Personnel following his successful leadership of the India business, which saw revenue grow from ₹2,300 crore to ₹7,000 crore. Additionally, Deloitte Haskins & Sells has been appointed as the new Statutory Auditor for a five-year term. These moves reflect a strengthening of governance and recognition of strong domestic performance where EBITDA margins expanded from 19% to 24%.
Key Highlights
Srikanth Velamakanni (Fractal AI CEO) appointed as Independent Director for a 5-year term from July 2026.
India Head Sandeep Khandelwal elevated to SMP; led India revenue growth from ₹2,300 Cr to ₹7,000 Cr.
India business EBITDA margins expanded from 19% to 24% and market rank improved from 16th to 9th.
Deloitte Haskins & Sells appointed as Statutory Auditors for a 5-year term starting from the 42nd AGM.
Dr. K P Krishnan re-appointed as Independent Director for a second 5-year term starting January 2027.
👀 What to Watch
Investors should view the elevation of the high-performing India head and the addition of an AI expert to the board as positive signs for future growth and digital transformation. The transition to a Big Four auditor (Deloitte) further strengthens corporate governance standards.
Dr. Reddy's Appoints Deloitte as Auditor and Elevates India Head After ₹7,000 Cr Revenue Milestone
Dr. Reddy's Laboratories has announced a series of governance and leadership updates, including the appointment of Deloitte Haskins & Sells as statutory auditors for a five-year term. The company elevated Sandeep Khandelwal to Senior Management Personnel, recognizing his role in growing the India business from ₹2,300 crore to ₹7,000 crore with EBITDA margins expanding to 24%. Furthermore, the appointment of Fractal co-founder Srikanth Velamakanni as an Independent Director signals a strategic push toward AI and technology integration. These moves collectively strengthen the company's board expertise and reward internal operational success.
Key Highlights
Deloitte Haskins & Sells, LLP appointed as Statutory Auditors for a 5-year term starting from the 42nd AGM.
India business revenue grew from ₹2,300 crore to ₹7,000 crore under elevated SMP Sandeep Khandelwal.
Domestic EBITDA margins expanded from 19% to 24%, with market rank improving from 16th to 9th.
Fractal Co-founder Srikanth Velamakanni joins the board as Independent Director, bringing AI and tech expertise.
Dr. K P Krishnan re-appointed as Independent Director for a second 5-year term starting January 2027.
👀 What to Watch
Investors should take confidence in the transition to a Big 4 auditor and the addition of high-caliber tech leadership to the board. The recognition of the India business head highlights the company's robust domestic growth engine, supporting a positive long-term outlook.
Dr. Reddy's FY26 Profit Drops 26% to ₹4,247 Cr; ₹8 Dividend Declared with July 10 Record Date
Dr. Reddy's reported a consolidated revenue of ₹33,593 crore for FY26, a modest 3.2% growth YoY, while net profit declined significantly by 25.8% to ₹4,247 crore. The Q4 performance was particularly weak, with profit falling to ₹220 crore compared to ₹1,587 crore in the previous year's quarter. Results were heavily impacted by a ₹453 crore shelf stock adjustment for Lenalidomide in the US and impairments from discontinued CAR-T R&D programs. Despite the profit dip, the board recommended a final dividend of ₹8 per share with a record date of July 10, 2026.
Key Highlights
FY26 Consolidated Revenue grew 3.2% YoY to ₹33,593 crore, while Net Profit fell 25.8% to ₹4,247 crore.
Q4 FY26 Revenue stood at ₹7,516 crore, impacted by a ₹453 crore (USD 50 million) shelf stock adjustment for generic Lenalidomide.
Recommended a final dividend of ₹8 per equity share (800% on FV of ₹1) for FY 2025-26.
Record date for dividend eligibility fixed as July 10, 2026, with the AGM scheduled for July 23, 2026.
Appointed Deloitte Haskins & Sells as Statutory Auditors for a 5-year term starting from the 42nd AGM.
👀 What to Watch
Investors should exercise caution as the sharp decline in Q4 margins and one-off revenue hits in the US market signal near-term headwinds. Monitor management commentary regarding the R&D pipeline rationalization and the impact of price erosion in the Global Generics segment.
Dr. Reddy's Declares Rs 8 Dividend; FY26 Net Profit Drops 25.8% to Rs 4,247 Crore
Dr. Reddy's Laboratories reported a consolidated revenue of Rs 33,593 crore for FY26, representing a modest 3% growth year-on-year. However, the annual net profit declined significantly by 25.8% to Rs 4,247 crore, down from Rs 5,725 crore in FY25. The company recommended a final dividend of Rs 8 per share, with a record date of July 10, 2026. Q4 results were specifically weighed down by a Rs 453 crore shelf stock adjustment for Lenalidomide in the US and the discontinuation of certain CAR-T R&D programs.
Key Highlights
Recommended a final dividend of Rs 8 per equity share of face value Rs 1 for FY25-26.
FY26 Consolidated Revenue reached Rs 33,593 crore, while Net Profit fell to Rs 4,247 crore.
Q4 FY26 revenue was impacted by a Rs 453 crore (USD 50 million) reduction due to price adjustments in the US market.
Results from operating activities for the full year decreased to Rs 5,055 crore from Rs 7,184 crore YoY.
Board approved the appointment of Deloitte Haskins & Sells, LLP as new Statutory Auditors for a 5-year term.
👀 What to Watch
Investors should exercise caution as the sharp decline in annual profitability and pricing pressure in the US generic market (Lenalidomide) signal headwinds. While the dividend provides some yield support, the focus should remain on the company's ability to offset R&D write-offs and stabilize margins in the coming quarters.
Dr. Reddy's Q4 Profit Drops 86% to ₹2,205M; Recommends ₹8 Dividend
Dr. Reddy's Laboratories reported a challenging Q4 FY26 with consolidated revenue declining 11.6% YoY to ₹75,162 million. Net profit for the quarter saw a sharp 86% decline to ₹2,205 million, significantly impacted by a ₹4,530 million shelf stock adjustment for Lenalidomide in the US and impairments from discontinued CAR-T therapy R&D programs. For the full year FY26, revenue grew slightly by 3.2% to ₹335,933 million, while annual profit fell 25.8% to ₹42,466 million. Despite the earnings hit, the board recommended a final dividend of ₹8 per share.
Key Highlights
Q4 FY26 Net Profit plummeted 86% YoY to ₹2,205 million from ₹15,873 million in the previous year.
Quarterly revenue fell 11.6% YoY to ₹75,162 million, impacted by a ₹4,530 million price adjustment claim in the US market.
Full-year FY26 profit after tax stood at ₹42,466 million, a 25.8% decrease from ₹57,245 million in FY25.
Board recommended a final dividend of ₹8 per equity share (800% on face value of ₹1) for FY26.
Impairment charges of ₹2,586 million were recorded in Q4 following the decision to discontinue certain CAR-T therapy R&D programs.
👀 What to Watch
Investors should exercise caution as the significant one-time revenue adjustments and R&D impairments have severely impacted quarterly margins. The focus should remain on management's outlook regarding US generic pricing stability and the growth trajectory of the Global Generics segment in FY27.
Dr. Reddy's First to Secure Health Canada Approval for Generic Semaglutide Injection
Dr. Reddy's Laboratories has received a Notice of Compliance from Health Canada for its generic Semaglutide Injection, making it the first generic player to receive marketing authorization in Canada. Canada is currently the world's second-largest market for Semaglutide, serving a diabetic population of approximately 3.9 million people, or 9.7% of the population. The approval covers 2 mg and 4 mg pens and was achieved ahead of the regulatory review target date. The company will utilize its 100% in-house API production, which strengthens its competitive position and margins in the complex peptide-based therapeutics space.
Key Highlights
First generic company to receive marketing authorization for Semaglutide Injection in Canada.
Canada represents the world's second-largest market for Semaglutide treatments per IQVIA data.
Targets a Canadian patient base of 3.9 million people living with diagnosed diabetes.
Approval includes 2 mg / pen and 4 mg / pen dosages with 100% in-house API manufacturing.
Authorization was granted ahead of Health Canada's official review target date.
👀 What to Watch
This approval establishes Dr. Reddy's as a frontrunner in the high-growth generic GLP-1 segment in a major regulated market. Investors should view this as a significant positive for long-term revenue growth and a validation of the company's complex generic capabilities.
Dr. Reddy's Clarifies Status of Semaglutide Injection Approval from Health Canada
Dr. Reddy's Laboratories has clarified that it is still awaiting the 'Notice of Compliance' for its Semaglutide Injection from Health Canada, confirming recent media reports. However, the company achieved a regulatory milestone by receiving 'Drug Identification Numbers (DINs)' for the product on April 22, 2026. This clarification follows significant stock price movement on April 23, 2026, and a subsequent inquiry from the National Stock Exchange. The company maintains that there is no undisclosed material information and continues to engage with Canadian authorities for final approval.
Key Highlights
Confirmed awaiting 'Notice of Compliance' (NOC) for Semaglutide Injection in Canada
Received 'Drug Identification Numbers (DINs)' from Health Canada on April 22, 2026
Clarification issued following stock price volatility on April 23, 2026
Semaglutide is identified as a major near-term trigger for the company's expansion
Company states no material impact currently as regulatory review is ongoing
👀 What to Watch
Investors should closely monitor the final 'Notice of Compliance' from Health Canada, as this will be the definitive catalyst for market entry. While the receipt of DINs is a positive step, the stock may experience volatility until the final approval is officially granted.
Dr. Reddy's Receives DINs for Semaglutide in Canada; Awaits Final Approval
Dr. Reddy's Laboratories clarified that it has received Drug Identification Numbers (DINs) for its Semaglutide Injection from Health Canada on April 22, 2026. However, the company is still awaiting the final 'Notice of Compliance' required for a commercial launch in the Canadian market. This clarification follows media reports regarding a delay in a major near-term trigger for the company. Semaglutide is a key product in the high-growth GLP-1 space, making its regulatory progress a significant event for investors.
Key Highlights
Received Drug Identification Numbers (DINs) from Health Canada on April 22, 2026
Still awaiting final 'Notice of Compliance' for Semaglutide Injection approval
Clarification issued following a CNBC TV18 news report dated April 23, 2026
Company remains committed to launching the product in Canada upon final approval
👀 What to Watch
Investors should monitor for the final 'Notice of Compliance' from Health Canada, as it is the final hurdle before commercialization. The receipt of DINs is a positive regulatory milestone, but the stock's near-term movement depends on the final launch timeline.
Dr. Reddy's Launches India's First Generic Semaglutide 'Obeda' at INR 4,200/Month
Dr. Reddy's has launched Obeda®, India's first DCGI-approved generic Semaglutide injection for Type 2 Diabetes, marking a strategic 'Day-1' entry into the GLP-1 therapy space. The product is priced competitively at INR 4,200 per month for both 2mg and 4mg strengths, targeting India's 101 million diabetic population. Developed entirely in-house from API to formulation, the launch demonstrates the company's advanced peptide science capabilities. This move positions Dr. Reddy's to capture significant market share in the high-growth metabolic disorder segment both in India and potentially global markets.
Key Highlights
First DCGI-approved generic Semaglutide in India with 'Day-1' entry post-patent expiry
Phase-III clinical study involving 312 participants confirmed non-inferior efficacy and safety
Competitive monthly treatment cost of INR 4,200 for both 2 mg and 4 mg strengths
Fully integrated in-house development and manufacturing of both API and formulation
Targeting a massive addressable market of 101 million diabetics and 136 million pre-diabetics in India
👀 What to Watch
Investors should view this as a major growth driver given the first-mover advantage in the blockbuster GLP-1 category. Monitor the adoption rate in India and the company's upcoming generic semaglutide launches in international markets.
Dr. Reddy's Partner Immutep Discontinues Phase III Lung Cancer Trial for Eftilagimod Alfa
Dr. Reddy's Laboratories has announced that the Phase III TACTI-004 trial for Eftilagimod Alfa (efti) will be discontinued following a planned interim futility analysis. The study was evaluating the drug for first-line non-small cell lung cancer, a key indication in Dr. Reddy's licensing agreement with Immutep. While Dr. Reddy's SA holds exclusive rights for the drug in regions excluding North America, Europe, Japan, and Greater China, the company has only made an upfront payment to date. This development represents a setback for the company's oncology pipeline in its licensed territories.
Key Highlights
Independent Data Monitoring Committee (IDMC) recommended halting the TACTI-004 Phase III study due to futility.
The trial focused on Eftilagimod Alfa for patients with first-line non-small cell lung cancer.
Dr. Reddy's SA holds licensing rights for all countries outside North America, Europe, Japan, and Greater China.
Financial exposure is currently limited as only the initial upfront payment has been made to Immutep.
Immutep is conducting a comprehensive review to determine the next steps for the Eftilagimod Alfa program.
👀 What to Watch
Investors should note this R&D setback which may lead to a minor valuation adjustment for the specialty pipeline. Monitor for any potential write-offs of the upfront payment in upcoming quarterly results.
Dr. Reddy's Wins Court Approval to Export Semaglutide to Non-Patent Markets
Dr. Reddy's Laboratories has clarified that the Delhi High Court has ruled in its favor regarding the manufacture and export of Semaglutide. The Division Bench upheld a previous order from March 09, 2026, which allows the company to produce the drug in India for export to countries where Novo Nordisk does not hold patent registrations. This decision follows a legal challenge by Novo Nordisk, which sought an interim injunction against Dr. Reddy's. While the matter remains sub-judice, this ruling provides a significant pathway for Dr. Reddy's to enter the high-growth GLP-1 market internationally.
Key Highlights
Delhi High Court Division Bench upheld the March 09, 2026, order allowing Semaglutide production.
Permission granted to export Semaglutide to international markets where Novo Nordisk lacks patent protection.
Court refused to grant an interim injunction requested by Danish pharmaceutical firm Novo Nordisk.
The ruling pertains to Semaglutide-containing products, a key category in diabetes and weight management.
Dr. Reddy's clarified that while the matter is sub-judice, the current ruling supports their manufacturing plans.
👀 What to Watch
Investors should monitor Dr. Reddy's progress in scaling Semaglutide exports to non-patent jurisdictions as it represents a major growth opportunity. The stock may see positive sentiment following this legal clearance for a high-demand product.
Dr. Reddy's Announces Senior Management Reshuffle; M V Ramana Named CEO of Global Generics
Dr. Reddy's Laboratories has announced a significant restructuring of its senior leadership team effective April 1, 2026. Mr. M S Madhu Sundar, who has 28 years of industrial experience, has been elevated to Global Head of Quality and Pharmacovigilance. Key executive roles have been redefined, including M V Ramana as CEO of Global Generics and Sanjay Sharma as Chief Operating Officer. This reshuffle appears to be a strategic move to streamline global manufacturing, quality, and product development operations.
Key Highlights
Mr. M S Madhu Sundar elevated to Global Head of Quality and PV, leveraging 28 years of industry expertise.
Mr. M V Ramana appointed as CEO of Global Generics, a core business segment for the company.
Mr. Sanjay Sharma designated as Chief Operating Officer (COO) effective April 1, 2026.
New leadership appointments made for Integrated Product Development (IPDO) and Consumer Health Organization.
👀 What to Watch
Investors should monitor the transition of these leaders into their new roles, particularly focusing on the execution of the Global Generics strategy. No immediate portfolio changes are recommended as these are internal elevations and planned role transitions.
Dr. Reddy's Cleared by US DOJ in FCPA Investigation; No Enforcement Action Recommended
Dr. Reddy's Laboratories has received a formal closure letter from the US Department of Justice (DOJ) regarding its investigation into potential Foreign Corrupt Practices Act (FCPA) violations. The inquiry, which began in November 2020, focused on allegations of improper payments to healthcare professionals in Ukraine and other jurisdictions. This follows a similar clearance from the US SEC received on February 23, 2026. The closure of both SEC and DOJ investigations without any recommended enforcement action effectively removes a significant long-term legal overhang for the company.
Key Highlights
US DOJ closes inquiry into FCPA violations involving payments in Ukraine and other countries.
No enforcement action recommended by the DOJ Criminal Division, Fraud Section in letter dated March 5, 2026.
Follows a previous clearance from the US SEC received on February 23, 2026.
The investigation had been a disclosed contingency since November 19, 2020.
👀 What to Watch
Investors should view this as a major positive development that eliminates a significant regulatory risk and potential financial liability. The stock may see positive sentiment as this multi-year legal cloud is finally cleared.
Dr. Reddy's Srikakulam Facility Receives VAI Status from USFDA, Inspection Closed
Dr. Reddy's Laboratories has received the Establishment Inspection Report (EIR) from the USFDA for its formulations manufacturing facility (FTO-SEZ PU01) in Srikakulam, Andhra Pradesh. The inspection, which was conducted in December 2025, has been classified as 'Voluntary Action Indicated (VAI)'. This classification indicates that the USFDA has concluded its review and the inspection is now officially closed. This resolution is a positive step as it removes regulatory uncertainty regarding future product approvals from this specific site.
Key Highlights
Received Establishment Inspection Report (EIR) from USFDA on March 4, 2026
USFDA classified the inspection outcome as 'Voluntary Action Indicated (VAI)'
Inspection at the Srikakulam (FTO-SEZ PU01) facility is now officially closed
Follows the initial GMP and Pre-Approval Inspection conducted in December 2025
👀 What to Watch
Investors should view this as a positive regulatory clearance that de-risks the company's US supply chain and product pipeline. No immediate action is required, but this strengthens the long-term outlook for the Srikakulam unit.
SEC Concludes FCPA Investigation into Dr. Reddy's; No Enforcement Action Recommended
Dr. Reddy's Laboratories has received a formal communication from the US SEC dated February 23, 2026, regarding its investigation into alleged improper payments to healthcare professionals. The investigation, which began in November 2020, focused on potential violations of the U.S. Foreign Corrupt Practices Act (FCPA) in Ukraine and other markets. The SEC has concluded its probe and does not intend to recommend any enforcement action against the company at this time. This resolution removes a significant long-term regulatory risk that has been a part of the company's disclosures for over five years.
Key Highlights
SEC investigation into FCPA compliance in Ukraine and other markets has been concluded as of February 23, 2026
No enforcement action recommended by the SEC staff at this time following a multi-year probe
Investigation originated from an anonymous complaint first disclosed on November 19, 2020
Company maintained full cooperation with DOJ, SEC, and SEBI throughout the investigation period
SEC notice issued under Securities Act Release No. 5310, indicating closure without formal exoneration
👀 What to Watch
Investors should view this as a significant positive development that removes a major legal overhang and potential financial liability. While the SEC has closed the matter, investors should keep a watch for a similar formal closure from the US Department of Justice (DOJ) to fully clear the legal risk.
Dr. Reddy's Acquires Progynova & Cyclo-Progynova for USD 32.15 Million to Enter HRT Segment
Dr. Reddy's has entered into a definitive agreement to acquire the trademarks and assets of Progynova and Cyclo-Progynova in India from UK-based Mercury Pharma Group for USD 32.15 million. This acquisition marks the company's strategic entry into the Hormone Replacement Therapy (HRT) segment, significantly strengthening its existing gynecology portfolio. Progynova is currently the #1 brand in the Estradiol represented market in India, with recorded sales of INR 100 crore as of December 2025. The deal allows Dr. Reddy's to leverage its domestic market access to expand the reach of these high-equity specialty brands.
Key Highlights
Acquisition of trademarks and related assets for India for a total consideration of USD 32.15 million.
Progynova is the #1 brand in the Estradiol represented pharmaceutical market in India with strong physician equity.
The acquired brand Progynova recorded annual sales of INR 100 crore as per IQVIA MAT December 2025.
Strategic entry into the Hormone Replacement Therapy (HRT) segment to bolster the domestic gynecology portfolio.
Includes Cyclo-Progynova, a combined HRT treatment currently not commercialized in India, providing future growth potential.
👀 What to Watch
Investors should view this as a positive strategic move to diversify the domestic branded portfolio with high-recall specialty brands. Monitor the successful integration and the potential launch of Cyclo-Progynova to drive incremental growth in the gynecology segment.
Dr. Reddy's Q3FY26: Revenue Grows 4.4% to ₹8,727 Cr; Adjusted EBITDA Margin at 24.8%
Dr. Reddy's reported a resilient Q3FY26 with revenue growth of 4.4% YoY to ₹8,727 crores, driven by double-digit growth in the base business excluding Lenalidomide. Reported PAT declined 14% YoY to ₹1,210 crores, impacted by lower Lenalidomide sales and a one-time provision for new Indian Labour Codes. Adjusted for this one-off, the EBITDA margin remained healthy at 24.8%. The company continues to strengthen its pipeline with the US BLA filing for Abatacept and DCGI approval for Semaglutide in India.
Key Highlights
Consolidated revenue reached ₹8,727 crores, up 4.4% YoY, supported by branded markets and favorable forex.
Adjusted EBITDA margin stood at 24.8% after excluding a one-time labor code provision; reported margin was 23.5%.
Net cash surplus remains robust at ₹3,069 crores ($342 million) as of December 31, 2025.
Received DCGI marketing authorization for Semaglutide injection in India and filed US BLA for Abatacept biosimilar.
USFDA issued a Complete Response Letter (CRL) for Denosumab biosimilar due to partner Alvotech's facility observations.
👀 What to Watch
Investors should monitor the ramp-up of the base business to offset the declining Lenalidomide contribution and track regulatory progress on the Semaglutide and Abatacept pipelines. The stock remains a solid play on biosimilars and emerging market growth, supported by a strong net-cash balance sheet.
